Exscientia to Screen 15,000 Drugs in Search for Coronavirus Treatment

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and working with Diamond Light Source and Oxford University, will apply its advanced biosensor platforms to rapidly screen this collection against key coronavirus drug targets involved in viral replication and entry into human cells.